Cabaletta is pushing a CAR-T approach in autoimmune disease that it says could reduce or eliminate chemotherapy preconditioning. At EULAR 2026, the company described early patient updates supporting its hypothesis that higher-dose, autologous CD19-directed in vivo CAR-T (rese-cel) may be delivered without the lymphocyte-depleting chemotherapy typically used to improve engraftment and response. Cabaletta is running a registrational study in myositis already enrolling, and it also has multiple autoimmune programs under its RESET platform, including systemic sclerosis and lupus. Company leaders positioned the potential shift as both a safety and convenience improvement for outpatient-style administration. Regulatory timing depends on registrational data, but the strategy underscores how autoimmune CAR-T development is increasingly focused on reducing regimen toxicity, not just efficacy.